Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26920896 |
US |
48 | 1 |
Rash erythematous, Pruritus, Skin burning sensation, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 202 | 26921184 |
US |
2 | |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, CALCIUM, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, PROGESTERONE, VITAMIN C, ERGOCALCIFEROL, BUPROPION HYDROCHLORIDE, TIRZEPATIDE, |
||||
| 203 | 26909697 |
US |
1 | |
Dermatitis atopic, Drug effect less than expected, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 204 | 26909894 |
US |
75 | 1 |
Sleep disorder due to a general medical condition, Pruritus, Rash, Skin discomfort, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 205 | 26910092 |
US |
2 | |
Oral herpes, Dermatitis atopic, |
||||
DUPILUMAB, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, FESOTERODINE FUMARATE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, LOSARTAN POTASSIUM, LOSARTAN, MELOXICAM, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, |
||||
| 206 | 26910176 |
EU |
59 | 1 |
Dermatitis atopic, |
||||
| 207 | 26910228 |
US |
72 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 208 | 26910287 |
US |
50 | 1 |
Sleep disorder due to a general medical condition, Hyperhidrosis, Discomfort, Skin ulcer, Pyrexia, Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 209 | 26910568 |
US |
2 | |
Dermatitis atopic, Rash, Dry eye, Skin exfoliation, Eye pruritus, Therapeutic response decreased, |
||||
DUPILUMAB, ALPRAZOLAM, BUPROPION HYDROCHLORIDE, CETIRIZINE HCL, CETIRIZINE, MONTELUKAST SODIUM, MONTELUKAST, ORAL SEMAGLUTIDE, RISPERIDONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, ALPRAZOLAM, |
||||
| 210 | 26910840 |
US |
49 | 1 |
Dermatitis atopic, Discomfort, Rash, Sleep disorder, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 211 | 26910851 |
US |
60 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, DULOXETINE HYDROCHLORIDE, DULOXETINE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LINACLOTIDE, RALOXIFENE, TRETINOIN, CETIRIZINE HYDROCHLORIDE, |
||||
| 212 | 26911510 |
US |
2 | |
Dermatitis atopic, Swelling face, Conjunctivitis, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 213 | 26911956 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 214 | 26912707 |
US |
78 | 2 |
Alopecia, Vision blurred, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, FUROSEMIDE, HYDROCHLOROTHIAZIDE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 215 | 26913520 |
CA |
55 | |
Psoriatic arthropathy, Fatigue, Pyrexia, Feeling cold, Chills, Pruritus, Psoriasis, Dermatitis atopic, Loss of personal independence in daily activities, Therapeutic product effect decreased, |
||||
SECUKINUMAB, |
||||
| 216 | 26913600 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, NEMOLIZUMAB-ILTO, DROSPIRENONE AND ETHINYL ESTRADIOL, FLUOXETINE HYDROCHLORIDE, |
||||
| 217 | 26914522 |
|||
Dermatitis atopic, |
||||
RUXOLITINIB, |
||||
| 218 | 26904867 |
US |
2 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 219 | 26904877 |
US |
10 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 220 | 26905009 |
US |
1 | |
Dermatitis atopic, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 221 | 26905103 |
US |
2 | |
Dermatitis atopic, Rash pruritic, Rash, |
||||
DUPILUMAB, |
||||
| 222 | 26905359 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 223 | 26905362 |
US |
3 | 2 |
Dermatitis atopic, Skin fissures, Erythema, Skin exfoliation, |
||||
DUPILUMAB, MONTELUKAST SODIUM, |
||||
| 224 | 26905372 |
US |
28 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 225 | 26905373 |
US |
42 | 2 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, Drug effective for unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 226 | 26905619 |
US |
12 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 227 | 26905630 |
US |
23 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 228 | 26905632 |
US |
57 | 1 |
Injection site pain, Product preparation issue, Dermatitis atopic, Skin irritation, Scratch, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 229 | 26906012 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 230 | 26906302 |
US |
15 | 2 |
Gout, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 231 | 26906352 |
US |
1 | |
Dermatitis atopic, Erythema, Swelling face, Inappropriate schedule of product administration, |
||||
DUPILUMAB, BETAMETHASONE DIPROPIONATE, |
||||
| 232 | 26906681 |
US |
35 | 2 |
Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 233 | 26906691 |
US |
61 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 234 | 26906693 |
US |
10 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 235 | 26906719 |
US |
71 | 2 |
Dermatitis atopic, Pruritus, Skin swelling, Injection site pain, Injection site swelling, Product preparation issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 236 | 26906728 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 237 | 26907044 |
US |
37 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 238 | 26907077 |
CA |
5 | 2 |
Pneumonia, Pyrexia, Pulmonary mass, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 239 | 26907081 |
US |
46 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 240 | 26907831 |
US |
25 | 2 |
Body tinea, Dermatitis atopic, Rash, Maternal exposure during pregnancy, |
||||
DUPILUMAB, |
||||
| 241 | 26907850 |
US |
48 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 242 | 26907857 |
US |
51 | 1 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, CITALOPRAM, CITALOPRAM HYDROBROMIDE, INSULIN LISPRO, EMPAGLIFLOZIN, INSULIN GLARGINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 243 | 26907858 |
US |
2 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 244 | 26908131 |
US |
16 | 1 |
Dermatitis atopic, Rash pruritic, Dry skin, |
||||
DUPILUMAB, |
||||
| 245 | 26908592 |
US |
||
Fatigue, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 246 | 26908596 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 247 | 26908815 |
US |
66 | 1 |
Dermatitis atopic, Pruritus, Erythema, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 248 | 26908820 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, DIPHENHYDRAMINE HCL, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, BUMETANIDE, BUMETANIDE, HYDROCODONE BITARTRATE AND ACETAMINOPHEN, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 249 | 26908831 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 250 | 26908903 |
US |
58 | 2 |
Back disorder, Dermatitis atopic, Blister, Arthralgia, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 251 | 26908985 |
US |
40 | 1 |
Skin exfoliation, Pruritus, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 252 | 26909401 |
US |
2 | |
Crying, Injection site pain, Dermatitis atopic, Pruritus, Dry skin, Therapeutic response decreased, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 253 | 26909403 |
US |
2 | |
Dermatitis atopic, Dermatitis allergic, Skin burning sensation, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, HYDROXYZINE, |
||||
| 254 | 26903652 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 255 | 26903675 |
US |
57 | 2 |
Dermatitis atopic, Pruritus, Acne, |
||||
DUPILUMAB, |
||||
| 256 | 26903727 |
US |
57 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 257 | 26903728 |
US |
63 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 258 | 26903735 |
US |
49 | 2 |
Dermatitis atopic, Incorrect product administration duration, |
||||
DUPILUMAB, |
||||
| 259 | 26903777 |
US |
6 | 2 |
Dermatitis atopic, Pruritus, Rash, |
||||
DUPILUMAB, |
||||
| 260 | 26903826 |
US |
2 | |
Dermatitis atopic, Hyperhidrosis, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 261 | 26903834 |
US |
31 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 262 | 26903835 |
US |
20 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 263 | 26903836 |
US |
40 | 2 |
Ocular hyperaemia, Dry eye, Dermatitis atopic, Eye pruritus, |
||||
DUPILUMAB, |
||||
| 264 | 26903899 |
US |
23 | 2 |
Asthma, Dermatitis atopic, Rash, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 265 | 26903924 |
US |
54 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 266 | 26903926 |
US |
30 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 267 | 26903960 |
US |
2 | |
Stress, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, MAGNESIUM, PERMETHRIN, PERMETHRIN CREAM 5% W/W, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ERGOCALCIFEROL, ERGOCALCIFEROL, |
||||
| 268 | 26903974 |
US |
71 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 269 | 26904035 |
US |
25 | |
Injection site haemorrhage, Dermatitis atopic, Device malfunction, Extra dose administered, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 270 | 26904050 |
US |
42 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 271 | 26904067 |
US |
16 | 1 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 272 | 26904077 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, OMALIZUMAB, |
||||
| 273 | 26904080 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 274 | 26904084 |
US |
60 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 275 | 26904093 |
US |
32 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 276 | 26904215 |
US |
49 | 2 |
Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 277 | 26904245 |
US |
55 | 2 |
Neurodermatitis, Dyshidrotic eczema, Dermatitis atopic, Skin exfoliation, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 278 | 26904290 |
US |
65 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 279 | 26902712 |
US |
73 | 1 |
Cataract, Memory impairment, Rash papular, Dermatitis atopic, Haemorrhage subcutaneous, Lacrimation increased, Unevaluable event, Animal scratch, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 280 | 26902734 |
US |
72 | 2 |
Dermatitis atopic, Dry skin, Skin exfoliation, |
||||
DUPILUMAB, ROSUVASTATIN CALCIUM, |
||||
| 281 | 26902750 |
US |
2 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 282 | 26902767 |
US |
5 | 1 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 283 | 26902808 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 284 | 26902813 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 285 | 26902828 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 286 | 26902830 |
US |
2 | |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 287 | 26902913 |
US |
1 | |
Dermatitis atopic, Rash, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 288 | 26902952 |
US |
70 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 289 | 26903056 |
US |
71 | 1 |
Dermatitis atopic, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 290 | 26903058 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 291 | 26903069 |
US |
44 | 2 |
Dermatitis, Chronic sinusitis, Condition aggravated, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 292 | 26903091 |
US |
62 | 1 |
Dermatitis atopic, Pruritus, Intentional product misuse, |
||||
DUPILUMAB, |
||||
| 293 | 26903191 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 294 | 26903197 |
US |
72 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, Dermatitis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 295 | 26903362 |
CA |
72 | 2 |
Secretion discharge, Back pain, Blister, Dyspnoea, Lower respiratory tract infection, Pain of skin, Chest discomfort, Erythema, Scab, Asthenia, Cough, Fatigue, Gastroenteritis viral, Neurodermatitis, Chest pain, COVID-19, Malaise, Off label use, Peripheral swelling, Skin weeping, Urticaria, Depressed mood, Gastrointestinal pain, Pruritus, Skin lesion, Dermatitis atopic, Sinusitis, Cellulitis, Chills, |
||||
DONEPEZIL HYDROCHLORIDE, DUPILUMAB, DUPILUMAB, DUPILUMAB, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, DIMENHYDRINATE, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, |
||||
| 296 | 26903595 |
KR |
||
Hepatic cirrhosis, Skin maceration, Dermatitis atopic, Skin exfoliation, Swelling face, Swelling of eyelid, Drug tolerance, Swelling, Erythema, Rash macular, Skin weeping, Vision blurred, Fatigue, Hepatitis, Therapeutic product effect decreased, Feeling hot, Cataract, Skin swelling, Rash erythematous, Folliculitis, Acne, Dermal cyst, Skin discharge, Jaundice, Erythema of eyelid, Pain, Hepatic enzyme increased, Eye movement disorder, Metabolic disorder, Pruritus, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 297 | 26897565 |
US |
1 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 298 | 26897568 |
US |
35 | 2 |
Dermatitis atopic, Eczema nummular, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 299 | 26897569 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 300 | 26897942 |
US |
12 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30